Journals / Retina-Vitreus / 2006 / Cilt: 14 - Sayı: 4

Assessment of toxicity of intravitreal triamcinolone acetonide in vitrectomized rabbit eyes

Vitrektomili tavşan gözlerinde intravitreal triamsinolon asetonid toksisitesinin tayini

Pages
245–250
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Doses above this limit may be very toxic to the retina.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: We evaluated the toxicity of Triamcinolone acetonide (TAA) which was administered intravitreally to vitrectomized rabbit eyes in the different doses through different time periods by using electrophysiological and pathological tests.
📊
Key Findings & Data:Materials and Methods: Vitrectomy was performed in both eyes of 54 rabbits and different doses of TAA were injected intravitreally into the right eyes.
💡
Conclusion & Impact:Doses above this limit may be very toxic to the retina.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: We evaluated the toxicity of Triamcinolone acetonide (TAA) which was administered intravitreally to vitrectomized rabbit eyes in the different doses through different time periods by using electrophysiological and pathological tests. Materials and Methods: Vitrectomy was performed in both eyes of 54 rabbits and different doses of TAA were injected intravitreally into the right eyes. Left eyes served as controls and received 0.2 ml. of balanced salt solution (BSS). Electroretinography was performed before surgery and at follow-up periods after TAA administration. Then the rabbits were sacrified at planned follow-up periods and the eyes were enucleated. Light microscopy examination was performed. Results: During the 28-days period, 4 mg. TAA group never showed any toxicity sign in electrophysiological, histopathological and ophtalmological examinations. 6 mg and 8 mg TAA groups showed a decline at b-wave amplitude in ERG (especially in 8 mg group and at the late phases of 6mg group), and necrosis, atrophy, disorganisation, fibrosis at the retinal layers in varying degrees according to duration period and dose of the drug. Conclusions: 4 mg triamcinolone acetonide can be administrated safely as an intravitreal application with its short effective half life and low side effect incidence. Doses above this limit may be very toxic to the retina.

Özet

Amaç: İntravitreal Triamsinolon Asetonidin (TAA) vitrektomili tavşan gözlerinde değişik zaman aralıklarında toksisitesini elektrofizyolojik ve patolojik testlerle değerlendirdik. Gereç ve Yöntem: Elli dört tavşanın her iki gözüne vitrektomi yapıldı ve sağ gözlerine değişik dozlarda TAA enjekte edildi. Sol gözlerine kontrol gözü olarak 0.2 ml BSS verildi. Cerrahi öncesi ve TAA uygulama sonrası takip zamanlarında elektroretinografi uygulandı. Tavşanlar planlı izlem anlarında öldürüldükten ve gözler enüklee edildikten sonra ışık mikroskobu ile incelendi. Bulgular: Yirmi sekiz günlük izlem süresince 4 mg TAA uygulanan grupta elektrofizyolojik, histopatolojik ve oftalmolojik incelemede toksisite bulgusu saptanmadı. İlacın kalış süresi ve dozuna bağlı olarak, 6 mg ve 8 mg TAA gruplarında ERG’de b dalgasında düşüklük (özellikle 8 mg’da ve 6 mg’ın geç dönemlerinde) ve retina tabakalarında değişik derecelerde nekroz, atrofi, dizorganizasyon ve fibrozis gelişimi gözlendi.

🔖

Cite This Article

SÖNMEZ, M., DOĞU, B., ÜNAL, M. H., ALKAÇ, İ. Ü., YILDIRIM, Ş., GÜLECEK, O. (2006). Assessment of toxicity of intravitreal triamcinolone acetonide in vitrectomized rabbit eyes. Retina-Vitreus, Cilt: 14 - Sayı: 4, 245–250. https://ajindex.com/articles/307781

References (16)

  1. Woods AC: Clinical and experimental observations on the use of ACTH and cortisone in ocular inflammatory disease. Am J Ophthalmol. 1950;33:1325-1349
  2. Graham RO, Peyman GA: Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch Ophthalmol. 1974;92:149-154
  3. Machemer R, Sugita G, Tano Y: Treatment of intraocular proliferation with intravitreal steroids. Trans Am Ophthalmol Soc. 1979;77:171-180
  4. Tano Y, Chandler D, Machemer R: Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 1980;90:810-816
  5. Park SS, Samiy N, Ruoff K,et al.: Effect of intravitreal dexamethasone in treatment of pneumococcal endophthalmitis in rabbits. Arch Ophthalmol. 1995;113:1324-1329
  6. Chandler DB, Rozakis G, de Juan E Jr, et al.: The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy. Am J Ophthalmol. 1985;99:686-690
  7. Antoszyk AN, Gottlieb JL, Machemer R, et al.: The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefe’s Arch Clin Exp Ophthalmol. 1993;231: 34-40
  8. Wilson CA, Berkowitz BA, Sato Y, et al.: Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol. 1992;110:1155-1159
  9. Martidis A, Duker JS, Greenberg PB, et al.: Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920-927
  10. Danis RP, Ciulla TA, Pratt LM, et al.: Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina. 2000;20:244-250
  11. Jonas JB, Degenring R, Kreissig I,et al.: Safety of intravitreal highdose reinjections of triamcinolone acetonide. Am J Ophthalmol. 2004;138:1054-1055
  12. Jarin RR, Teoh SC, Lim TH: Resolution of severe macular oedema in adult Coat’s syndrome with high-dose intravitreal triamcinolone acetonide. Eye. 2006;20:163-165
  13. Chang S: Vitrectomy. InYanoff M, Duker J S: Ophthalmology The Mosby Co St.Louis. 2004:792-795
  14. Jonas JB, Hayler JK, Söfker A, et al.: Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol. 2001;131:468-471
  15. Jonas JB, Hayler JK, Panda-Jonas S.: Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol. 2000;84:1064-1067
  16. Tsujikawa A, Fujihara M, Iwawaki T,et al.: